
Neurogene Inc., a New York-based pharmaceutical company, specializes in developing genetic medicines for rare neurological diseases.
Neurogene Inc., founded in New York, is a pharmaceutical company dedicated to developing genetic medicines for rare and devastating neurological diseases. Their core mission is to innovate and execute robust scientific solutions to create life-changing treatments for patients and their families. Neurogene's pipeline focuses on gene therapy, aiming to address the high unmet needs in the realm of neurological disorders.
Notable figures affiliated with Neurogene include experienced scientists and industry leaders in genetic medicine. The company has attracted significant investment from leading biotech venture capital firms, underscoring confidence in its potential. Neurogene's key achievements include advancing a promising gene therapy pipeline and making strides toward clinical trials. The overall impact of Neurogene lies in its potential to revolutionize treatment for rare neurological diseases, offering hope to affected individuals and their families.

Ironshore Pharmaceuticals

Corxel Pharmaceuticals

Kedrion Biopharma

Invetx

NeuroGenetic Pharmaceuticals

Ultragenyx Pharmaceutical
ultragenyx.com

Neuron23
neuron23.com

Greenland Mines
anewmeds.com

Empyrean Neuroscience
empyrean.bio

Neurocrine Biosciences
neurocrine.com

Harmony Biosciences

Nutra Pharma
nutrapharma.com

Neurovia

Ovid Therapeutics
ovidrx.com

Axsome Therapeutics
axsome.com

Neuraly
neuralymed.com
Intellect Neurosciences
intellectns.com

NeuroPro Therapeutics

Opus Genetics
opusgtx.com

Woolsey Pharmaceuticals
woolseypharma.com
Neurogene's most recent funding round was for $115M (USD) in December 2020.
As of Dec 16, 2020, Neurogene has disclosed funding of $183.5M (USD).